Noxxon Pharma NV, of Berlin, said it secured €380,000 (US$441,451) of additional financing from existing investors in the form of a convertible bond, which will convert to shares at the terms of a future equity financing round, or starting on Oct. 1, 2018, at the investors option at the market price, which will be reset quarterly to the 10-day volume-weighted average price.